Dermatology is a meeting point between our pharmaceutical and dermo-cosmetic R&D teams. It is the cornerstone that captures our desire to be present from“health to beauty.” In the pharmaceutical field, our efforts today focus mainly on infantile hemangioma and onco-dermatological diseases.


A major therapeutic discovery

hemangiome.jpgInfantile hemangioma, which affects 10% of infants, is a benign tumor that develops in the first weeks of life. It may have major functional or esthetic repercussions.

Following the signing in 2008 of an exclusive partnership agreement with the University of Bordeaux and the Bordeaux University Hospital Center (France), Pierre Fabre Dermatology obtained a marketing authorization request in 2014 to the European (EMA) and American (FDA) agencies.


oncodermatologie.jpgA public health challenge

Skin cancer has been on the rise for 30 years and is now a real public health challenge in terms of both prevention and therapy. It is estimated that in the near future one person in six will develop skin cancer. The individualization of active substances and the development of new topical treatments for these cancers, especially basal-cell carcinoma and actinic keratosis, are more than ever priorities. With our considerable expertise in both oncology and dermatology, onco-dermatology has become a logical focus of research for Pierre Fabre Laboratories.


recherche-dermo.jpgSkin expertise

By maintaining privileged connections with Pierre Fabre’s pharmaceutical research teams and developing numerous partnerships with public research bodies, our dermo-cosmetics researchers have developed indisputable expertise in the related fields of dermatology and cosmetology. In close cooperation with top international specialists they have conducted a number of important clinical studies, thereby contributing to the development of new dermo-cosmetic concepts and to the expansion of knowledge about the skin.